CARVEDILOL (carvedilol) by Aurobindo Pharma is adrenergic alpha-antagonists [moa]. Approved for alpha-adrenergic blocker [epc]. First approved in 2007.
Adrenergic alpha-Antagonists
alpha-Adrenergic Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
Worked on CARVEDILOL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.